Skip to main content

Table 1 Demographic and clinical characteristics of patients

From: Impact of hemoperfusion with polymyxin B added to hemofiltration in patients with endotoxic shock: a case–control study

 

Global

(n = 18)

Control patients

(n = 9)

Toraymyxin treated patients

(n = 9)

p value

Age: years, mean (SD)

67.5 (9.9)

66 (10)

69.1 (9.5)

0.52

Male: n (%)

6 (33.3)

2 (22)

4 (44)

0.31

Apache II: mean (SD)

20.67 (4.7)

21.2 (5.3)

20.1 (4.3)

0.63

SOFA baseline mean (SD)

11.3 (2.6)

11.6 (2.9)

11 (2.4)

0.6

Sepsis focus n (%)

 Peritonitis

9 (50)

4 (44)

4 (44)

0.4

 Biliary tract

4 (23)

2 (22)

3 (33)

 

 Urinary tract

5 (27)

3 (33)

2 (22)

 

RIFLE score (%)

 Injury

28

33

22

0.5

 Failure

72

64

78

 

Vasoactive drugs (days), mean (SD)

4.9 (3.8)

4.5 (3.4)

5.2 (4.3)

0.72

IMV (days), mean (SD)

9.4 (8.8)

6.3 (8)

12.4 (8.8)

0.03

CRRT (days), mean (SD)

6 (6)

3.5 (1.9)

8.5 (7.6)

0.01

ICU LOS (days), mean (SD)

19.8 (16.8)

14.7 (16)

24.9 (17)

0.21

Hospital LOS (days), mean (SD)

36 (31)

32 (34)

39.5 (29)

0.64

ICU mortality (%)

38.9

44.4

33.3

0.5

Hospital mortality (%)

38.9

44.4

33.3

0.5

  1. APACHE II Acute Physiology and Chronic Health Evaluation II, SD standard deviation, SOFA Sequential Organ Failure Assessment, IMV invasive mechanical ventilation, CRRT continuous renal replacement therapy, LOS length of stay, ICU intensive care unit